)
Daniel Kennedy
CBO
Resolution Therapeutics
Daniel is an accomplished business development executive with over 20 years of experience building partnerships, leading licensing deals, and driving strategic transactions in pharma and biotech. Previously he served as Vice President, Business Development at Immunocore plc (NASDAQ: IMCR), and led business development and alliance management at Achillion Pharmaceuticals, prior to its acquisition by Alexion Pharmaceuticals (NASDAQ: ALXN) for $930 million in cash plus up to $300 million in contingent value rights. Dan has held positions at Schering-Plough and GSK, where he held diverse roles spanning business development transactions for R&D, alliance management, global corporate development, US commercial marketing, brand launch pricing, and payer contracting.
Sessions
-
22-Jun-2026Theater 1Resolution Therapeutics
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}